The Rosetta Resolver system, which is being distributed by Agilent Technologies, is designed to be used with a variety of third-party and internally-developed DNA microarray technologies. This trademark is owned by Europroteome AG. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, September 28, 2012.
#EUROPROTEOME AG MONEYHOUSE SERIAL NUMBER#
The USPTO has given the EPTAGON trademark a serial number of 78307151. 'Using cutting-edge technology platforms for RNA and proteomics, we operate a high-throughput functional genomics laboratory to focus on research in the field of epithelial. On Tuesday, September 30, 2003, a trademark application was filed for EPTAGON with the United States Patent and Trademark Office. On the same address there are 69 other active companies registered. In the commercial register the company Loxodrome Maritime AG is registered under the UID CHE-240.125.732. EUROPROTEOME is an ideal partner to achieve this objective."Ĭhristian Knobloch, M.D., Vice President Business Development, EUROPROTEOME, added: "We are very pleased that the value of EEUROPROTEOME's capabilities to merge both molecular and clinical data is being recognized by a top tier pharmaceutical company. Europroteome AG licenses Rosetta Resolver Gene Expression Data Analysis system. Awema AG, bisher in Pfäffikon, CHE-106.961.499, Aktiengesellschaft (SHAB Nr. The Rosetta Resolver system, which is being distributed by Agilent Technologies, is designed to be used with a variety of third-party and internally-developed DNA microarray technologies, including Agilent DNA microarrays. Under Notifications you will find all commercial register changes, the most recent one was made on. This will allow for the stratification of patients who will benefit most from targeted cancer therapeutics. Europroteome Ag: Assignee: Application Publication: 09381266 20020150569: Diagnosis Of Epithelial Cell Abnormalities Diagnosis Of Epithelial Cell Abnormalities: 4/24. "Molecular profiling of tissue specimens from cancer patients will be an important step in the development of novel cancer drugs. Karl Sanders, Head Therapeutic Area Oncology at ALTANA Pharma AG. "We believe this collaboration will greatly enhance our knowledge about the clinical relevance of novel cancer targets," said Dr. Ulrich Traugott Email Address Found 1 email address listing:.
#EUROPROTEOME AG MONEYHOUSE FREE#
The molecular data will then be aligned with a selected set of clinical data such as cancer stage and disease progression in order to assess disease associated expression signatures and prioritize molecular target candidates for therapeutic intervention with novel drugs and accompanying diagnostics for disease control. Chief Executive Officer Europroteome Ag Preparing Ulrichs profile View Ulrichs Email (Its Free) 5 free lookups per month. Under the agreement, EUROPROTEOME will use its proprietary collection of purified human cancer cells to analyze molecular expression of a panel of cancer targets. EUROPROTEOME AG announced that it has entered into a collaboration for evaluation of approaches for molecular profiling of tissue specimens from cancer patients with ALTANA Pharma AG.
0 kommentar(er)
